Mabwell Announces the CDE Approval of Novel Nectin-4 Targeting ADC to Initiate Phase III Clinical Trial for the Treatment of Cervical Cancer
SHANGHAI,Aug. 23,2024-- Mabwell (688062.SH),an innovative biopharmaceutical company with entire industry chain,announced that its submission to the Center for Drug Evaluation (CDE) of the National Med